2015
DOI: 10.1007/s40264-015-0284-x
|View full text |Cite
|
Sign up to set email alerts
|

Organ-On-A-Chip: Development and Clinical Prospects Toward Toxicity Assessment with an Emphasis on Bone Marrow

Abstract: Conventional approaches for toxicity evaluation of drugs and chemicals, such as animal tests, can be impractical due to the large experimental scale and the immunological differences between species. Organ-on-a-chip models have recently been recognized as a prominent alternative to conventional toxicity tests aiming to simulate the human in vivo physiology. This review focuses on the organ-on-a-chip applications for high-throughput screening of candidate drugs against toxicity, with a particular emphasis on bo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(17 citation statements)
references
References 97 publications
(108 reference statements)
0
17
0
Order By: Relevance
“…As such, new cell lines were developed that retained human relevance and the capacity to differentiate into any cell that makes up the human body without the ethical issues associated with their use. Extracting somatic cells (e.g., blood cells, testicular, keratinocytes, and pancreatic) from patients and reprograming them to human iPSCs enable researchers to fabricate patient specific platforms for drug discovery and disease modeling purposes . Some cell types can be directly reprogrammed into other lineages .…”
Section: Cell Sources For Tissue Engineeringmentioning
confidence: 99%
See 1 more Smart Citation
“…As such, new cell lines were developed that retained human relevance and the capacity to differentiate into any cell that makes up the human body without the ethical issues associated with their use. Extracting somatic cells (e.g., blood cells, testicular, keratinocytes, and pancreatic) from patients and reprograming them to human iPSCs enable researchers to fabricate patient specific platforms for drug discovery and disease modeling purposes . Some cell types can be directly reprogrammed into other lineages .…”
Section: Cell Sources For Tissue Engineeringmentioning
confidence: 99%
“…This tissue is responsible for continuously producing blood cells in our bodies via hematopoietic SCs . Hematopoietic SCs in bone marrow exist in a specific cell niche so that hematopoietic SCs maintain their phenotype and function . The bone marrow niche has been shown to be critical for self‐renewal and differentiation of hematopoietic SCs into blood cell lineage …”
Section: Current Organ‐on‐a‐chip Platformsmentioning
confidence: 99%
“…In conclusion, the here presented bone marrow model demonstrates for the first time the successful long-term culture of functional multipotent HSCs in a dynamic environment. The model surpasses all previously presented 3D bone marrow models in culturing time of HSCs as well as in mimicking the in vivo environment (Kim et al, 2015). Predestining it as a model for sophisticated in vitro drug testing, thus, serving as an alternative to animal testing.…”
Section: Resultsmentioning
confidence: 88%
“…This construct was subsequently transferred to a microfluidic device and cultured for one week. (Kim et al, 2015; Torisawa et al, 2014). Unfortunately, no model was able to mimic the human hematopoietic stem cell niche meaning the continued sustainment of primitive HSCs while simultaneously allowing various hematopoietic populations to differentiate into their respective progeny.…”
Section: Introductionmentioning
confidence: 99%
“…Bone marrow is a sponge‐like, flexible, soft, incredibly complex tissue, with the responsibility of continuously producing blood and immune cells in the body . The bone‐marrow‐on‐a‐chip is beneficial to determine the effect of various chemical agents, drugs, and immune cells since the bone marrow plays a key role in immune system due to its hematopoietic activities.…”
Section: Stem‐cell Based Organ‐on‐chip Platformsmentioning
confidence: 99%